T he organic calcium channel blocking drugs (CCBs) have been used for 3 decades as a mainstay of vasodilator therapy to treat hypertension, coronary vasospasm, and other diseases of abnormal arterial tone. 1 The 3 structural families of CCBs share a common mechanism of action to dilate small arteries and arterioles; they bind to the pore-forming ␣ 1C subunit of the L-type Ca 2ϩ channel (LTCC) in arterial smooth muscle cells (SMCs) to reduce open-state probability. 2 However, the usefulness of the CCBs is limited by their inability to dilate the venous circulation. Ankle edema, a common side effect of CCB therapy, is thought to result partly from CCB-induced dilation of arterioles in the absence of venous dilation; the resulting increase in capillary pressure promotes fluid exudation. [3] [4] [5] [6] Additionally, the antihypertensive effect of the CCBs mediated by arterial dilation may be buffered by persistent venoconstriction that sustains preload to maintain blood pressure elevation. [7] [8] [9] [10] Although it is well recognized clinically that the vasodilator effect of CCBs is limited to the arterial circulation, the mechanism that confers venous resistance to this class of drugs in vivo is unknown. One possibility is that the LTCCs expressed in arteries and veins are fundamentally different in their biophysical or pharmacological properties. In this regard, only several studies have characterized the biophysical properties and drug profiles of the LTCCs in patch-clamped venous SMCs or even documented their contribution to the contraction of isolated veins. Surprisingly, these studies suggest that similar to arteries, LTCCs in the SMCs of large veins retain sensitivity to the CCBs. For example, depolarization-induced constrictions of porcine femoral and saphenous veins are sensitive to calcium channel blockade. 11 Additionally, voltage-elicited Ca 2ϩ currents in patch-clamped SMCs from canine saphenous vein are blocked by nanomolar concentrations of CCBs. The biophysical properties of these channels appear indistinguishable from their arterial counterparts. 12 Finally, the LTCCs in rabbit portal vein myocytes also display a customary profile of voltage-dependent opening, channel kinetics, and sensitivity to blockade by nisoldipine, verapamil and diltiazem. 13 Collectively, these findings suggest that the SMCs of conduit veins express prototypic LTCCs, although patch-clamp studies in SMCs isolated from veins or venules that regulate changes in venous capacitance apparently are unavailable.
In contrast, small veins and venules from diverse origins fail to dilate to the CCBs, suggesting a lack of functional LTCCs in these venous SMCs in situ. In striated muscle of spontaneously hypertensive rats, the LTCC blockers verapamil, nifedipine (Nif), and felodipine selectively dilate arterioles but not venules. 14 Similarly, Nif only dilates the arterioles but not venules in the hamster cheek pouch, although the venules are sensitive to other dilator stimuli. 15 Finally, Nif and benipidine dilate the arterioles but not venules of the rat mesenteric circulation. 16, 17 Thus, the insensitivity of the venous circulation to CCB-induced dilation, that is clinically recognized also, is observed experimentally in small veins.
Using the second order branches of small mesenteric arteries (MAs) and mesenteric veins (MVs) of the rat as a model, the present study was designed to resolve the mechanisms that confer venous insensitivity to CCB-induced dilation. We used depolarizing concentrations of high KCl to directly activate voltage-gated LTCCs to induce constriction and thereby circumvent complex receptor-mediated signaling pathways that may differ between arterial and venous SMCs. Complementary vascular reactivity and Ca 2ϩ imaging studies were performed in pressurized MAs and MVs. Additionally, Western blot and patchclamp studies compared the expression, properties, and CCB sensitivity of LTCCs between arterial and venous preparations.
Methods
An expanded Methods section is available in the Online Data Supplement at http://circres.ahajournals.org.
Diameter and Membrane Potential Recording in Pressurized Vessels
Procedures using animals were performed at the University of Arkansas for Medical Sciences in accordance with the NIH Guide for the Care and Use of Laboratory Animals. Second order MAs and MVs were dissected from 10-week-old male Sprague Dawley rats (Harlan) and cannulated with tapered glass micropipettes. The inflow pipette was connected to a reservoir to control intraluminal pressure. 18 Arteries and veins were pressurized at their native pressures of 80 and 6 mm Hg, respectively. Internal diameters were recorded on-line using an upright microscope/Spot RT camera with images captured by Metavue acquisition software (Metamorph). Intracellular membrane potential (E m ) was recorded using glass microelectrodes. 19 
Ca

2؉ Imaging in Fluo-4 -Loaded Vessels
Second order MAs and MVs were cleaned of adhered fat and connective tissue and loaded with the Ca 2ϩ indicator fluo-4 (2 mol/L) plus pluronic acid (0.01%) in physiological salt solution at room temperature for 1.5 hours in the dark. Images were captured using a ϫ10 S Fluor objective (NAϭ0.5) on a Nikon TE2000-U microscope with a QImaging Retiga 2000R camera and iVision software (version 4.0.14, Biovision Inc) that also was used for analysis. For fluorescence quantitation, a region of interest in the lumen of the vessel was chosen, avoiding the vessel walls and sympathetic nerves.
Detection of the ␣ 1C Subunit
Whole-cell protein homogenates were prepared from MAs and MVs pooled from 2 rats. The expression level of the pore-forming ␣ 1C subunit of the LTCC was assessed by Western blotting using a polyclonal antibody (Alomone Labs, Jerusalem, Israel). 20 
Recording of Ca 2؉ Channel Currents
SMCs were enzymatically isolated from rat MAs and MVs. 19 -21 Whole-cell Ca 2ϩ channel currents were recorded using standard pulse protocols and solutions. 22 Single LTCC current openings in freshly isolated MA and MV SMCs were obtained in the cell-attached mode.
Results
Depolarization-Induced Constriction in MVs Is Resistant to Nif
Direct depolarization of isolated veins by high concentrations of KCl has been used to directly evaluate the contribution of LTCC-mediated Ca 2ϩ influx to venoconstriction. 11 We used glass microelectrodes to compare the depolarizing responses of second order branches of the rat MAs and MVs to high (60 mmol/L) KCl to ensure an equal voltage stimulus for LTCC opening in both preparations. Figure 1A and 1B shows that KCl depolarization robustly reduced the E m of MAs and MVs. The average resting E m in MAs and MVs were Ϫ47Ϯ2 mV and Ϫ46Ϯ3 mV, respectively (nϭ6). Figure 1C demonstrates that 60 mmol/L KCl was equally effective in depolarizing the MAs (⌬16Ϯ2 mV) and MVs (⌬14Ϯ2 mV). The same depolarizing stimulus also similarly reduced the diameter of the MAs and MVs by 70Ϯ6% and 68Ϯ6%, respectively ( Figure 2A ). In spite of these similarities, whereas preincubation of MAs with Nif (1 mol/L) for 10 minutes inhibited KCl constriction by 93%, similar constrictions of the MVs were resistant to 1 or 10 mol/L Nif, showing only a 20% and 15% loss of constriction, respectively (Figure 2A and 2B). Neuronally released norepinephrine did not contribute to KCl constriction of small MVs, because the ␣-adrenergic receptor antagonist phentolamine (1 mol/L) did not blunt this response (Online Figure I) . Finally, Nif and a structurally unrelated CCB, diltiazem, failed to reverse established KCl constrictions of rat MVs, whereas both drugs concentration-dependently reversed arterial constriction ( Figure 2C and 2D) .
Studies using fluo-4 -loaded MAs and MVs verified that LTCCs contribute less to depolarization-induced Ca 2ϩ mobilization in venous compared to arterial SMCs. In drug-free solution, KCl induced a 3.9-fold and 2.9-fold rise in cytosolic free Ca 2ϩ ([Ca] i ) that did not differ significantly between MAs and MVs, respectively ( Figure 3A and 3B) . After a 10-minute incubation with 10 mol/L Nif, KCl failed to increase [Ca] i in MAs ( Figure 3C and 3D) . However, KCl still induced a 2.0-fold rise in [Ca] i in MVs implying that the venous SMCs mobilized Ca 2ϩ in the absence of functional LTCCs ( Figure 3C and 3D ).
Similar Expression of ␣ 1C in Arterial and Venous SMCs
Considering the resistance of KCl constrictions in MVs to CCBs and the diminished contribution of venous LTCCs to [Ca] i elevation during depolarization, we explored whether MVs express fewer LTCC ␣ 1C pore-forming subunits compared to MAs. Western blots using protein lysates from MAs and MVs showed that the doublet immunoreactive band corresponding to the long and short forms of ␣ 1C was 48% less in MVs ( Figure 4A , top blot; nϭ4). However, after normalization of ␣ 1C to the reduced smooth muscle ␣-actin signal in venous lysates ( Figure 4A , lower blot; nϭ4) to account for the lower SMC content in MVs, 23 densitometric analysis suggested that the MAs and MVs express similar levels of the ␣ 1C protein ( Figure 4B ).
LTCCs in Patch-Clamped Arterial and Venous SMCs Have Similar Properties
Subsequently, we used whole-cell patch-clamp methods to determine whether the ␣ 1C immunoreactive signal detected in venous lysates corresponded to functional LTCCs. Inward currents of similar amplitudes were observed in venous and arterial SMCs ( Figure 5A , 5C, and 5F). Peak Ba 2ϩ current elicited at ϩ26 mV was similar between MA and MV SMCs (Ϫ6.4Ϯ0.7 pA/pF and Ϫ6.6Ϯ1.1 pA/pF, respectively) (Figure 5A ; nϭ14, 7). Membrane capacitance also was similar (MAs: 14.8Ϯ0.9 pF; MVs: 15.7Ϯ1.3 pF). Standard pulse protocols were used to obtain the half-maximal activation and inactivation voltages ( Figure 5B ). 23 These analyses provided similar values between arterial and venous SMCs for halfmaximal (V 1/2 ) current activation (MAs: 12.2Ϯ1.1 mV; MVs: 12.0Ϯ0.6 mV) and inactivation (MAs: Ϫ9.3Ϯ3.3 mV; MVs: Ϫ8.6Ϯ2.7 mV), revealing no voltage-dependent abnormalities of the venous channels. Interestingly, exposure of the patch-clamped SMCs to Nif at a concentration (100 nmol/L) that failed to dilate the MVs but fully dilated the MAs ( Figure 2C ) was equally effective in blocking inward current in both cell types ( Figure 5C , 5D, 5F, and 5G). Peak Ba 2ϩ current in arterial SMCs was blocked 56% by Nif compared to 55% inhibition in venous SMCs ( Figure 5E and 5H). Thus, although KCl constrictions in isolated, pressurized MVs were insensitive to CCBs, the venous SMCs subjected to whole-cell patch-clamp conditions expressed prototypic Nif-sensitive LTCCs with properties indistinguishable from the arterial channels.
Depleting Intracellular Ca 2؉ Restores Venous SMC Sensitivity to CCBs
The divergent observations that LTCCs in MVs did not contribute to KCl constriction ( Figure 2 ), whereas depolarization elicited whole-cell LTCC currents in dialyzed SMCs of MVs ( Figure 5 ), led us to consider the possibility that venous LTCCs are inactivated by cytosolic factors in situ, conferring resistance to CCB-induced dilation. In this regard, a rise in [Ca] i during cell excitation is recognized as a negative feedback mechanism that inactivates LTCCs in a variety of cell types. 24 -26 Initially, we determined whether Ca 2ϩ influx through store-operated channel inactivated LTCCs during depolarization of MVs. Pressurized MVs were preincubated with gadolinium (Gd 3ϩ ) or lanthanum (La 3ϩ ) to nonselectively block store-operated channels. We observed that neither Gd 3ϩ (100 mol/L) nor La 3ϩ (100 mol/L) reduced the amplitude of KCl constrictions in MVs or conferred venous sensitivity to Nif ( Figure 6A and 6B).
Because the sarcoplasmic reticulum is in close proximity to the plasma membrane in some venous SMCs, 27 we next explored whether depleting intracellular Ca 2ϩ stores using the SERCA inhibitor thapsigargin (Thaps) (1 mol/L) 28 could restore depolarization-induced Ca 2ϩ influx through LTCCs and thereby confer sensitivity to CCBs. Because Thaps alone robustly constricted MVs (data not shown), vessels were kept in nominally Ca 2ϩ -free physiological salt solution during exposure to Thaps and then extracellular Ca 2ϩ (1.5 mmol/L) was restored concurrently with depolarizing KCl. Depletion of intracellular Ca 2ϩ stores with Thaps reduced KCl constriction in MVs by 41%. However, after Thaps treatment, Nif blocked KCl constrictions in rat MVs by 80% (nϭ6) ( Figure 6C ). We also preincubated the MVs in 10 mmol/L caffeine (Caf) to deplete intracellular Ca 2ϩ stores by increasing ryanodine receptor activity. 28 Caf did not alter KCl constrictions, but similar to Thaps, KCl constrictions of MVs were blunted 61% by Nif in the presence of Caf ( Figure 6D ). Ryanodine, which opens ryanodine receptors to a full conductance state also depletes intracellular Ca 2ϩ stores. 28 Ryanodine (10 nmol/L) also did not affect KCl constrictions in MVs, but in its presence, Nif blunted KCl constrictions by 62% ( Figure 6E ). Finally, we used 2-aminoethoxydiphenyl borate (2-APB), a nonselective IP 3 receptor blocker and storeoperated channel blocker, 28 to deplete intracellular Ca 2ϩ stores. We observed that whereas 2-APB (100 mol/L) did not alter KCl constrictions in MVs, Nif reduced KCl constrictions by 86% in the presence of 2-APB ( Figure 6F ). Thus, depletion of intracellular Ca 2ϩ stores in venous SMCs using four different pharmacological agents apparently restored depolarizationelicited Ca 2ϩ influx through LTCCs in MVs. As a final proof-of-principle that the lack of effect of CCBs in MVs relates to a "silencing" of LTCCs in venous SMCs by intracellular Ca 2ϩ stores, we compared the open-state probability (NP o ) of LTCCs in arterial and venous SMCs using the cell-attached patch configuration that minimally disturbs the intracellular milieu. Reducing the patch potential from Ϫ70 to Ϫ10 mV resulted in dense and often stacked single-channel currents in cell-attached patches of SMCs of MAs ( Figure 7A (nϭ14, 7) . B, Voltage-dependent activation and inactivation were not significantly different between SMCs of MAs (nϭ9, 14) and MVs (nϭ5, 9). C through E, Arterial SMCs treated with Nif (100 nmol/L) showed a 56% reduction in LTCC channel current density (nϭ9 to 14). F through H, Venous SMCs showed a similar level of Nif-induced block of 55% (nϭ4 to 7). *PϽ0.05, significant difference from control (Con) in the same preparation.
Thakali et al Silent L-Type Ca 2؉ Channels in VeinsDiscussion
The organic CCBs have been used for several decades to treat hypertension and vasospasm with particular emphasis on the dihydropyridine class that includes Nif as a selective vasodilator. It is widely recognized that the CCBs exert their antihypertensive effect by reducing the open-state probability of LTCCs in arterial SMCs to lower afterload but that they have little suppressant effect on the tone of the venous circulation. 9,31-33 To our knowledge, the present study provides the first mechanistic explanation for the resistance of veins to CCB therapies, a characteristic that may limit their antihypertensive action and contribute to adverse effects. [3] [4] [5] [6] Based on our findings, we propose that the SMCs of small MVs express prototypic LTCCs that retain the same sensitivity to CCB-induced blockade as arterial SMCs. However, during vascular activation, the LTCCs in the SMCs of small veins are inactivated by Ca 2ϩ from intracellular stores. Thus, small veins express phenotypically normal but "silent" LTCCs whose function is only revealed after Ca 2ϩ store depletion disinhibits the channels to enable Ca 2ϩ influx.
In this regard, it is well recognized that Ca 2ϩ influx through LTCCs primarily mediates arterial but not venous tone in vivo, 9,31-33 although there is experimental evidence that some larger veins retain sensitivity to CCBs. 11 The mechanism that confers the resistance of small veins to CCB-induced dilation has been elusive, and it may not be fair to extend our observations to all venous beds, because there are special venous beds, such as the portal veins and pulmonary veins, that are exposed to high PO 2 and high pressure, respectively, that may respond differently to CCBs because of their unique environments. Our studies used cannulated second order rat MAs and MVs, which were pressurized at their high and low in situ intraluminal pressures, respectively, as an experimental model to identify these mechanisms. We first considered the possibility that a more negative resting E m below the voltage required for LTCC activation and/or an inability of KCl to depolarize the venous SMCs may explain the apparent lack of depolarization-induced Ca 2ϩ influx through LTCC in MVs. The factors that regulate stores also resulted in MV sensitivity to Nif (nϭ5 to 6), as did incubating with 2-APB (100 mol/L) (F) (nϭ6). *PϽ0.05, significant difference from control (Con); †PϽ0.05, significant difference between Thaps, Caf, ryanodine, or 2-APB in the presence and absence of Nif.
resting E m in veins are poorly understood, and the in situ E m in rat MVs is reportedly more negative than in the MAs, 34 although the in vitro values of resting E m may not differ. 35 Indeed, we observed similar levels of resting E m between pressurized rat MAs and MVs and the addition of 60 mmol/L KCl induced a comparable depolarization. Similarly, the lack of LTCCdependent constriction in MVs could not be attributed to fewer channels, because MAs and MVs expressed similar levels of pore-forming ␣ 1C subunits and venous SMCs exhibited wholecell Ca 2ϩ channel currents indistinguishable in properties and densities from arterial SMCs. Thus, the functional LTCCs in SMCs of MVs appear to be prototypic channels. However, the paucity of unitary LTCC currents in cell-attached patches of venous SMCs indicated that when the cytosol is minimally disturbed in veins, the LTCCs are either not activated by depolarization or are inactivated by a cytosolic influence that is retained in the cell-attached configuration but lost during cell dialysis in whole-cell recording. Our findings that the Ca 2ϩ chelator BAPTA-AM increased unitary LTCC currents in venous SMCs paired with the demonstration that pharmacological depletion of intracellular Ca 2ϩ stores confers sensitivity of venous constriction to CCBs provide strong evidence that intracellular Ca 2ϩ stores inactivate venous LTCCs during SMC depolarization. However, we cannot rule out the possibility that LTCC-mediated Ca 2ϩ entry is partly buffered by SR uptake that acts as a sink for Ca 2ϩ entering the cell as postulated by the superficial buffer barrier hypothesis. 36 Our proposal that the silencing of LTCCs in venous SMCs is mediated by Ca 2ϩ inactivation concurs with the recognition of this process as an important biophysical property of LTCCs that acts as a negative-feedback mechanism to limit voltage-gated Ca 2ϩ entry during cell excitation. -dependent inactivation of LTCCs to limit action potential duration. 39 The process of Ca 2ϩ inactivation of LTCCs also may assume a physiological role in vascular SMCs, although there are only a few findings in this regard. 40 -42 However, we report here that intracellular Ca 2ϩ stores in venous SMCs appear to nearly eliminate a contribution of Ca 2ϩ influx through LTCCs to constriction, thereby acting as a powerful physiological switch that determines the source of activator Ca 2ϩ in this cell type. Additionally, this process also may account for the resistance of venous SMCs to the dilator effect of CCBs, because the inactivation of LTCCs negates a contribution of voltage-gated Ca 2ϩ influx to venous contraction. Thus, a physiological event formerly assigned only a modulatory role in SMCs may have a major impact on the fundamental Ca 2ϩ handling mechanisms that underlie venous contraction and also determine its pharmacological sensitivity to vasodilator drugs.
Our findings also suggest that venous SMCs rely on other mechanisms for increasing cytosolic Ca 2ϩ , which must differ from the LTCCs that predominate in arterial SMCs. Storeoperated and receptor-operated Ca 2ϩ channels are present on the plasma membrane of SMCs and additional voltage-gated Ca 2ϩ channel types (ie, T-type channels) have been proposed. [43] [44] [45] Ryanodine receptors and IP 3 receptors located in the membrane of the sarcoplasmic reticulum also have been described. 27 We observed that the rat MVs still can contract robustly to KClinduced depolarization even in the presence of high concentrations of Nif or diltiazem, suggesting that depolarization triggers the release of intracellular Ca 2ϩ in venous SMCs independently of LTCCs activity under our conditions. Indeed, the SR is present in close proximity to the plasma membrane in the SMCs of many blood vessel types including the small pulmonary arteries, aorta, and small mesenteric arteries and veins, 45 suggesting coupling of intracellular Ca 2ϩ stores and plasma membrane ion channels. This interaction has been demonstrated in human cerebral arteries, in which Ca 2ϩ release from ryanodine receptors (ie, Ca 2ϩ sparks) activates the plasma membrane high-conductance, Ca 2ϩ -activated K ϩ channel. 46 Thus, we speculate that there may be a difference in sarcoplasmic reticulumplasma membrane association of ion channels in veins compared to arteries, such that intracellular Ca 2ϩ stores in veins can interact with and silence plasma membrane LTCCs.
Limitations
There are several key limitations in our study that should be acknowledged. First, the in vivo environment of arteries and veins differs in many respects including oxygen tension, pH, and intraluminal pressure and these factors may alter vascular reactivity. We accounted for the different intraluminal pressures in our experiment by pressurizing arteries and veins near their physiological pressures. However, we exposed both MAs and MVs to physiological solutions bubbled with a 95% O 2 /5% CO 2 gas mixture to attain a pH value of 7.4. Thus, differences in PO 2 , CO 2 , and extracellular pH did not account for venous resistance to CCBs in our study but conceivably could modulate sensitivity in vivo. Second, CCBs, including Nif, can influence vascular tone aside from their pharmacological block of LTCCs that mediates the main dilator effect. The CCBs may induce NO release from the endothelium 47 and scavenge superoxide. 48 Because the endothelium was not removed from the rat small MAs and MVs in our study, it is possible that endothelial-derived NO complemented the dilator effects of Nif attributed to pharmacological block of LTCCs in SMCs. Third, to our knowledge, the types of ion channels and their regulation in venous SMCs have not been rigorously investigated. Thus, it is possible that the populations of ion channels expressed in arteries and veins are different. Although highly speculative, the lack of LTCC activity in veins also could relate to uncharacterized interactions with other cytosolic or membrane proteins. For example, in mouse motor nerve terminals, normally silent LTCCs are revealed by blockade of Ca 2ϩ -activated K ϩ channels. 49
Perspectives
Our study has highlighted important differences in mechanisms of vasoconstriction between small MAs and MVs, and the findings suggest that venous depolarization-induced constriction can occur independently of Ca 2ϩ influx via LTCCs. Our findings suggest that although prototypic LTCCs are expressed in the plasma membrane of venous SMCs, these channels are "silenced" in situ by intracellular Ca 2ϩ stores. To our knowledge, this is the first report providing an explanation for why CCBs are selective arterial dilators in humans and animals in vivo, whereas veins fail to respond to these important vasodilator agents. Conversely, defining the unique mechanisms of venoconstriction may present novel targets for new blood pressurelowering drugs that selectively target the venous circulation.
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Novelty and Significance
What Is Known?
• Calcium channel blockers block Ca 2ϩ entry through voltage-gated L-type Ca 2ϩ channels and are widely prescribed as antihypertensive medications to lower high blood pressure.
• These drugs block Ca 2ϩ influx into arteries but not veins to increase vessel diameter and lower blood pressure, but the reason why veins fail to dilate to calcium channel blockers is unclear.
What New Information Does This Article Contribute?
• The present study shows that Ca 2ϩ channel blockers prevent the constriction of small arteries but not veins from the rat mesenteric circulation; the mesenteric circulation is a key vascular bed that controls blood pressure in animals and humans.
• Next, we show that L-type Ca 2ϩ channels are present in similar numbers in mesenteric arteries and veins, but the Ca 2ϩ channels in veins are not functional.
• Finally, we provide evidence that in veins, Ca 2ϩ from intracellular stores "silences" L-type Ca 2ϩ channels.
The reason why Ca 2ϩ channel blocking drugs lower blood pressure by dilating arteries but not veins is unknown. Our goal was to determine why veins fail to dilate in response to this class of drugs. Using the rat mesenteric circulation as a model, we observed that although L-type Ca 2ϩ channels exist in both arteries and veins, Ca 2ϩ channel blockers prevent arteries but not veins from constricting. However, depleting intracellular Ca 2ϩ stores in the muscle cells of veins restores sensitivity to Ca 2ϩ channel blockers. These findings suggest that intracellular Ca 2ϩ stores "silence" L-type Ca 2ϩ channels in veins, thereby negating their contribution to constriction. Thus, we provide evidence for a novel mechanism of "Ca 2ϩ channel silencing" that confers venous insensitivity to Ca 2ϩ channel blockers. Our data suggest that Ca 2ϩ from intracellular stores may mediate venoconstriction, and these Ca 2ϩ -mobilizing pathways may represent targets for the development of new venodilator therapies. In the clinical setting, the selective dilation of the venous circulation reduces blood return to the heart to lower its workload, which is beneficial in some cardiovascular diseases such as heart failure.
1
ONLINE SUPPLEMENT
Detailed Methods:
Isolated vessel perfusion:
All animal studies were performed in accordance with the Guide for the Care and Use of Laboratory Animals at the University of Arkansas for Medical Sciences. Second order mesenteric arteries and their corresponding veins from 10-week old male Sprague Dawley rats (Harlan) were dissected, cleaned of adhered fat and connective tissue, and placed in physiological salt solution (PSS) containing (in mM): NaCl, 119; KCl, 4.7; MgSO 4 , 1.17; NaHCO 3 , 24.0; EDTA, 0.026; NaH 2 PO 4 , 1.17; glucose, 5.55; CaCl 2 , 1.6, in a heated (37°C) chamber bubbled with 95% O 2 , 5% CO 2 . Vessels were cannulated with tapered glass micropipettes (100-200 µm diameter, Living Systems Inc) and secured on the cannulae with 10-0 monofilament. The inflow pipette was connected to a reservoir system that allowed control of intraluminal pressure. Arteries were pressurized at 80 mmHg, and veins at 6 mmHg. After mounting, vessels were equilibrated for 1 hour, exchanging the PSS every 15 minutes. Depolarization-induced constriction was elicited by iso-osmotic substitution of KCl (60 mmol/L) for NaCl in the PSS. All other drugs were added directly to the perfusion chamber. Nifedipine (1 and 10 µmol/L), caffeine (10 mmol/L), ryanodine (10 nmol/L), or vehicle (0.1% ethanol, PSS, or 0.1% dH 2 O, respectively) was added to the bath 10 minutes before recording the KCl (60 mmol/L)-induced constriction. When depleting intracellular Ca 2+ with thapsigargin, vessels were initially washed 5 times in nominally Ca 2+ -free PSS (Ca 2+ was omitted from the PSS), and then incubated in thapsigargin (1 µmol/L) or vehicle (0.1% DMSO) for 20 minutes. Then vessels were depolarized with KCl (60 mmol/L), and extracellular Ca 2+ (1.5 mmol/L) added back to the bath to compare depolarization-induced constriction in the presence and absence of intracellular Ca 2+ . Internal diameters were recorded on-line using an upright microscope/Spot RT camera with images captured by Metavue acquisition software (Metamorph). 
Membrane potential measurements:
Intracellular membrane potential (E m ) was measured in pressurized, perfused mesenteric arteries and veins by glass microelectrodes filled with 3 M KCl that had tip resistances of 50-80 MΩ. The microelectrodes were fitted over a silver chloride wire that was connected to a preamplifier probe mounted to a micromanipulator. The probe was connected to a high-impedance amplifier, which was connected to a digital-to-analog converter that was connected to a computer. Data were collected with WinDaq data acquisition software. Impalements were considered to be successful if an abrupt negative drop in voltage upon cell entry occurred, a stable recording was maintained for a minimum of 5 s and an immediate return to baseline upon withdrawal of the microelectrode. 
Ca
2+ imaging in Fluo-4 loaded vessels: Second order MA and MV were cleaned of adhered fat and connective tissue and incubated with the Ca 2+ indicator fluo-4 (2 µmol/L) plus pluronic acid (0.01%) in PSS at room temperature for 1.5 hours in the dark. Vessels were then placed in fresh PSS for 30 minutes before mounting, perfusing and pressurizing them as mentioned above. The vessels were lowered to the bottom of the chamber so that we could bring the vessel in to focus using an objective with a short working distance. Three images (200 ms exposure), 30 seconds apart, were captured for basal Ca 2+ levels, then vessels were depolarized with KCl (60 mmol/L) and 12 images (200 ms exposure), 30 seconds apart, were captured for calculating the change in intracellular Ca 2+ . In a subset of experiments, vessels were incubated with nifedipine (10 µmol/L) 10 minutes prior to depolarization with KCl. After washing out the KCl, F min was measured after rinsing the vessels 5 times with Ca 2+ -free PSS containing 1 mmol/L EGTA. The F max was measured after incubating the vessels in PSS with 10 mmol/L Ca 2+ and the Ca 2+ ionophore ionomycin (10 µmol/L). Images were captured using a 10X S Fluor objective (NA = 0.5) on a Nikon TE2000-U microscope, with a QImaging Retiga 2000R camera and iVision software (version 4.0.14, Biovision Inc.) that also was used for analysis. For fluorescence quantitation, a region of interest in the lumen of the vessel was chosen, avoiding the vessel walls and sympathetic nerves.
Western blot analysis:
Rat MA and MV were isolated, dissected, cleaned of fat and connective tissue and snap-frozen in liquid nitrogen. Vessels were homogenized with dounce homogenizers (15 minutes on ice) and protein isolated with lysis buffer containing (in mM): HEPES, 50; NaCl, 150; EGTA, 1; MgCl 2 , 1.5; PMSF, 0.01; 1% Triton X-100, 10% glycerol and 5 µg/mL of the following protease inhibitors: leupeptin, aprotinin, and antipain. Forty micrograms of total protein were loaded on pre-cast 4-15% gradient SDSpolyacrylamide gels (Biorad), and electrophoresed at 140 mV. After electrophoresis, proteins were transferred to nitrocellulose (80 mV for 1.5 hours), membranes blocked in 5% milk for 3 hours at room temperature and incubated with a polyclonal anti-α 1C antibody (1:200 in 5% milk, Alomone Labs) or monoclonal smooth muscle α-actin antibody (1:5000 in 5% milk, Sigma-Aldrich) overnight at 4°C. After rinsing blots in tris-buffered saline (+0.5% Tween-20, 6 times with 10 minutes per rinse), blots were incubated with an anti-rabbit secondary antibody (1:1000) or an anti-mouse secondary antibody (1:10,000) for one hour at room temperature and developed using standard chemiluminescence protocols. 
Smooth muscle cell dissociation:
Mesenteric arteries and veins, cleaned of adhered fat and connective tissue, were placed in 1 ml of dissociation solution (145 mM NaCl, 4 mM KCl, 1 mM MgCl 2 , 0.16 mM CaCl 2 , 10 mM HEPES, 10 mM glucose; pH 7.4) containing bovine serum albumin (BSA, 0.5 mg/ml) for 10 minutes at room temperature. The vessels were then transferred into 1 mL of dissociation solution (+BSA) with papain (26 U/ml, Worthing) and dithiothreitol (1 mg/ml), and incubated for 30 min in a water bath at 37°C. Vessels were then placed in 1 mL of dissociation solution (+BSA) with collagenase (1.95 U/mL, Type F, SigmaAldrich) plus elastase (0.5 mg/ml, Worthington) and soybean trypsin inhibitor (1 mg/mL, Sigma-Aldrich) for 8 minutes at 37°C. Vessels were gently triturated with a glass pipette and then placed in ice-cold dissociation solution (+BSA). Smooth muscle cells were dissociated by mild trituration with a glass pipette every 15 minutes until single cells were isolated.
2-4
Whole-cell patch clamp:
Smooth muscle cells from mesenteric arteries and veins were enzymatically isolated as described above and studied within 6 hours. Recordings were obtained at 25°C using 10 mmol/l BaCl 2 as a charge carrier to limit current rundown. With the use of -70 mV as the constant interpulse holding potential, whole-cell currents were elicited in response to progressive 8-mV voltage steps (400 ms) from -70 mV to +58 mV. Peak current amplitudes were normalized to membrane capacitance to account for different cell sizes. The pipette solution consisted of (in mmol/l): 145 cesium glutamate, 1 MgCl 2 , 10 HEPES, 10 EGTA, and 3 Na 2 ATP (pH 7.3 with CsOH). The bath solution contained (in mmol/l): 10 BaCl 2 , 135 TEA, 1 MgCl 2 , 10 HEPES, and 10 glucose (pH 7.3 with TEA-OH). In a subset of cells, 100 nM nifedipine (Sigma) was used to verify the identity of Ca L channel currents. Current-voltage curves of were plotted after normalizing peak current to cell capacitance. 23 Voltage-dependent activation and inactivation curves were fit by the Boltzmann equation: I/I max = A 2 + (A 1 -A 2 )/(1 + exp((V -V 1/2 )/s), where V is the command voltage, V 1/2 is the half-maximal potential, s is the slope factor, A 1 is the maximum value of the ratio I/I max (fixed at 1), and A 2 is the minimum value of the ratio I/I max .Data analysis was performed using Clampfit 8 (Molecular Devices) and Origin (Origin Corp., MA). 5, 6 Cell-attached single channel recording:
Single LTCC currents were recorded in the cell-attached mode using 90 mmol/L Ba 2+ in the pipette solution to serve as a charge carrier. The composition of the pipette solution was (in mmol/L): 90 BaCl 2 , 30 TEA, 10 HEPES (pH 7.3 with TEA-OH). The LTCC agonist BAY K8644 (1 µmol/L) was added to the pipette solution. The ionic composition of the bath solution was (in mmol/L): 145 KCl, 10 glucose, 5
